Tesamorelin: The Peptide that Targets Visceral Fat
Tesamorelin is a Growth Hormone-releasing peptide studied for its ability to reduce visceral fat.
Visceral fat sits deeper than subcutaneous fat. It wraps around the liver, intestines, and other organs.
Visceral fat is linked to a higher risk of insulin resistance, heart disease, and metabolic syndrome, and it doesn’t always respond to diet and exercise.
Tesamorelin is one of the most researched peptides for addressing this specific type of fat.
This article covers what Tesamorelin is, how it works, what the research shows, and what Defy Medical’s Peptide Therapy patients can expect from this protocol.
What Is Tesamorelin?
Tesamorelin is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH), a hormone your body produces naturally to signal the pituitary gland.
When Tesamorelin binds to GHRH receptors, it prompts the pituitary gland to release more Human Growth Hormone (HGH).
The liver then converts HGH into Insulin-like Growth Factor 1 (IGF-1), which carries out many of Growth Hormone’s downstream effects on metabolism and tissue.
This indirect approach is different from taking HGH directly. Tesamorelin amplifies the body’s own signal rather than replacing the hormone itself, which helps preserve HGH’s natural release pattern.
Tesamorelin is chemically related to Sermorelin, another Growth Hormone-Releasing Peptide, though Tesamorelin has been studied specifically for its effect on visceral fat.
Tesamorelin is typically given as a once-daily subcutaneous injection, usually in the abdomen. It often comes as a powder (lyophilized), which is reconstituted with sterile water before use.
Defy Medical providers will create a customized protocol, including dose and injection timing, based on each patient’s labs and goals.
How Does Tesamorelin Target Visceral Fat?
Visceral fat is more metabolically active than subcutaneous fat (the fat just under the skin). That means it functions more like an organ, releasing hormones, fatty acids, and other chemicals. It also has a deeper effect on negative health outcomes like insulin resistance and inflammation.
Growth Hormone and IGF-1 both play a role in lipolysis (fat burning), and research suggests visceral fat responds more readily to Growth Hormone signaling than fat elsewhere in the body. This is why Tesamorelin has shown such promising effects on visceral fat specifically.
Sermorelin also triggers hGH release, but it doesn’t reduce visceral fat in the same way. This is likely because Tesamorelin is more potent than Sermorelin and triggers more sustained hGH levels, which in turns boosts lipolysis.
In your consultation, a Defy Medical provider will discuss how Tesamorelin fits alongside other therapies, including Hormone Therapy, GLP-1 medication, and other peptides.
What Does the Research Show About Tesamorelin and Visceral Fat?
In two 26-week clinical trials, adults treated with Tesamorelin saw visceral fat reductions of 14% to 18%, measured by imaging, compared with slight increases in the placebo group.
Patients who continued treatment for a full year maintained those reductions, while patients who switched to a placebo saw their visceral fat begin to increase again.
This pattern suggests a longer Tesamorelin protocol may support a shift in fat storage that lasts beyond the treatment.
Visceral fat is difficult to reduce through lifestyle changes alone, which is why researchers have studied Tesamorelin for this purpose.
Some patients in these studies also saw improvements in triglycerides and other metabolic markers associated with visceral fat. Tesamorelin isn’t typically used as a treatment for high cholesterol or triglycerides on its own, but this shows promising health benefits of a long-term protocol.
Defy Medical’s providers use follow-up labs and monitoring, including IGF-1 levels, to track how a patient responds and adjust the protocol accordingly.
What Are the Potential Side Effects of Tesamorelin?
Like other Growth Hormone-Releasing Peptides, Tesamorelin carries some common, mild to moderate side effects.
- Redness, itching, or irritation at the injection site
- Joint pain
- Muscle aches
- Swelling in the hands or feet
- Tingling or numbness in the extremities
These effects are generally described as mild in clinical studies and tend to improve as the body adjusts to treatment.
Growth Hormone signaling can also raise blood sugar, so patients with insulin resistance or diabetes may need closer monitoring while using Tesamorelin.
Tesamorelin isn’t appropriate for everyone. Providers screen for active cancer, pituitary conditions, and pregnancy before starting treatment, since Growth Hormone signaling can influence how existing tissue grows. That’s why it’s important to take Tesamorelin under medical guidance and to order medication from reputable sources.
Some patients also report mild fluid retention, which is usually manageable with dose adjustments.
Who May Be a Fit for Tesamorelin?
Whether Tesamorelin is right for you depends on overall health, hormone levels, and treatment goals.
Tesamorelin is most often considered by patients focused on reducing visceral fat as part of broader body composition and longevity goals. It’s not typically used on its own for general weight loss, though it may be combined with GLP-1 medication as appropriate.
Defy Medical providers confirm candidacy with comprehensive lab work, a full health history, and an in-depth consultation before starting treatment.
Patients already using Testosterone Replacement Therapy (TRT) or Bioidentical Hormone Replacement Therapy (BHRT) can often add Tesamorelin to their existing protocol.
For example, a patient with stubborn abdominal fat despite consistent diet, exercise, and TRT might discuss Tesamorelin with their provider as an addition to their current plan.
What Lab Work Is Required Before Starting Tesamorelin?
Before starting Tesamorelin, Defy Medical requires a baseline lab panel to confirm appropriateness and screen for contraindications (reasons not to take the medication).
- Insulin-like Growth Factor 1 (IGF-1): This measures the hormone your body produces in response to Growth Hormone signaling.
- Comprehensive Metabolic Panel (CMP-14): This panel checks kidney function, liver function, and blood sugar, since Growth Hormone-Releasing Peptides can affect glucose metabolism.
- Complete Blood Count (CBC): This test screens for infection, inflammation, and other blood-related conditions before starting a new peptide.
- Fasting Insulin: This measures how your body manages blood sugar at rest, which providers watch closely given Growth Hormone’s effect on insulin sensitivity.
- Hemoglobin A1c: This reflects your average blood sugar over the past several months and helps establish a baseline before treatment begins.
- Prostate-Specific Antigen (for male patients only): This test helps rule out prostate concerns before starting a therapy that raises Growth Hormone and IGF-1.
These labs give your provider an in-depth look at your health, plus provide a baseline for future follow-up testing to monitor treatment.
Peptide Therapy with Defy Medical
Defy Medical offers access to Peptide Therapy, including Tesamorelin, for qualifying patients as part of an individualized care plan.
Patients begin with a consultation and comprehensive labs. From there, our providers build a protocol tailored to the patient’s individual needs, with ongoing monitoring to assess response and adjust as needed.
Ready to learn more?
Get StartedRelated Health Articles
What is the Wolverine Peptide Stack?
A lot of supplements claim to be the best Testosterone booster, but those claims aren't always proven and results may be overexaggerated.
Learn More About What is the Wolverine Peptide Stack?
BPC-157: The Peptide Behind Recovery Conversations
BPC-157 is a peptide that has generated significant interest for recovery. The research behind BPC-157 offers a look at how the body heals.
Learn More About BPC-157: The Peptide Behind Recovery Conversations
What is The Glow Peptide Stack?
A lot of supplements claim to be the best Testosterone booster, but those claims aren't always proven and results may be overexaggerated.
Learn More About What is The Glow Peptide Stack?